EUVIMEDEUVIMED entdecken
Crossref

ARV-806, a PROTAC KRAS G12D Degrader, in Patients with KRAS G12D–Mutated Advanced Solid Tumors: Preliminary Phase 1 Results

Y.R. Murciano-Goroff, N.J. Gandhi, A.I. Spira, A. Patnaik, D.S. Hong, I. Garrido-Laguna, S. Sharma, S.R. Chandana, B. O'Neil, D.L. Bajor, L. Wu, M.J. Borad und 7 weitere

European Journal of Cancer · 2026-11 · 248 · 117457

DOI: 10.1016/j.ejca.2026.117457 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von Y.R. Murciano-Goroff und 18 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Murciano-Goroff, Y., Gandhi, N., Spira, A., Patnaik, A., Hong, D., Garrido-Laguna, I., Sharma, S., Chandana, S., O'Neil, B., Bajor, D., Wu, L., Borad, M., Kim, R., Teh, J., Duperret, E., Gong, J., Zhi, E., Pouliot, G., & LoRusso, P. (2026). ARV-806, a PROTAC KRAS G12D Degrader, in Patients with KRAS G12D–Mutated Advanced Solid Tumors: Preliminary Phase 1 Results. European Journal of Cancer, 248, 117457. https://doi.org/10.1016/j.ejca.2026.117457

Vancouver

Murciano-Goroff Y, Gandhi N, Spira A, Patnaik A, Hong D, Garrido-Laguna I, et al. ARV-806, a PROTAC KRAS G12D Degrader, in Patients with KRAS G12D–Mutated Advanced Solid Tumors: Preliminary Phase 1 Results. European Journal of Cancer. 2026;248:117457. doi:10.1016/j.ejca.2026.117457

BibTeX
@article{MurcianoGoroff2026,
  author = {Murciano-Goroff, Y.R. and Gandhi, N.J. and Spira, A.I. and Patnaik, A. and Hong, D.S. and Garrido-Laguna, I. and Sharma, S. and Chandana, S.R. and O'Neil, B. and Bajor, D.L. and Wu, L. and Borad, M.J. and Kim, R.D. and Teh, J. and Duperret, E. and Gong, J. and Zhi, E. and Pouliot, G. and LoRusso, P.},
  title = {ARV-806, a PROTAC KRAS G12D Degrader, in Patients with KRAS G12D–Mutated Advanced Solid Tumors: Preliminary Phase 1 Results},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {248},
  pages = {117457},
  doi = {10.1016/j.ejca.2026.117457}
}
Kostenlos starten →